SNPs Give LACTB Oncogene‐Like Functions and Prompt Tumor Progression via Dual‐Regulating p53
Advanced Science · 2024
DOI: 10.1002/advs.202405907 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Guanyu Huang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Musculoskeletal Oncology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China. Hauptthemen laut MEDLINE: Osteosarcoma, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, Natural Science Foundation of Guangdong Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
LACTB is identified as a tumor suppressor in several tumors. However, preliminary study reveals that LACTB is overexpressed in osteosarcoma and indicates poor prognosis. Two missense mutations (rs34317102 and rs2729835) exist simultaneously in 92.31% of osteosarcoma patients and cause M5L and R469K double mutations in LACTB, suggesting the biologic function of LACTB protein may be altered in osteosarcoma. Moreover, LACTB M5L+R469K overexpression can promote malignant progression in different tumors, which suggests that the M5L and R469K mutations confer oncogene‐like functions to LACTB. Mechanistically, LACTB M5L+R469K not only reduces the wild type p53 via enhancing PSMB7 catalytic activity, but also protects p53 R156P protein from lysosomal degradation, which suggesting LACTB M5L+R469K is a dual‐regulator for wt‐p53 and mutant p53, and derive oncogene‐like functions. More importantly, clavulanate potassium, a bacterial β ‐lactamase inhibitor, can inhibit osteosarcoma proliferation and sensitize osteosarcoma to cisplatin by binding and blocking LACTB M5L+R469K . These findings revealed that the M5L and R469K double mutations can diminish the tumor suppressive ability of wild type LACTB and provide oncogene‐like functions to LACTB. Inhibiting LACTB M5L+R469K can suppress the progression of osteosarcoma harbouring wild‐type or mutant p53. Clavulanate potassium is a promising drug by targeting LACTB M5L+R469K ‐p53 pathway for the treatment of osteosarcoma patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Musculoskeletal Oncology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China.
- Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China.
- NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical…
ORCID-Profile: Junqiang Yin
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- Natural Science Foundation of Guangdong Province
- National Natural Science Foundation of China
- The New Talent Program of The First Affiliated Hospital, Sun Yat-sen University
Zitieren
APA
Huang, G., Zhang, J., Xu, Y., Wu, F., Fu, Y., Zhang, X., Yin, H., You, Y., Zhao, P., Liu, W., Shen, J., & Yin, J. (2024). SNPs Give LACTB Oncogene‐Like Functions and Prompt Tumor Progression via Dual‐Regulating p53. Advanced Science. https://doi.org/10.1002/advs.202405907
Vancouver
Huang G, Zhang J, Xu Y, Wu F, Fu Y, Zhang X, et al. SNPs Give LACTB Oncogene‐Like Functions and Prompt Tumor Progression via Dual‐Regulating p53. Advanced Science. 2024. doi:10.1002/advs.202405907
BibTeX
@article{Huang2024,
author = {Huang, Guanyu and Zhang, Jiajun and Xu, Yu and Wu, Fei and Fu, Yiwei and Zhang, Xuelin and Yin, Hanxiao and You, Yuanyuan and Zhao, Peng and Liu, Weihai and Shen, Jingnan and Yin, Junqiang},
title = {SNPs Give LACTB Oncogene‐Like Functions and Prompt Tumor Progression via Dual‐Regulating p53},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202405907}
}
EUVIMED